{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:52:24Z","timestamp":1787014344157,"version":"build-2736575974"},"reference-count":89,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Giant cell arteritis (GCA) is the most common systemic vasculitis in older adults and is a medical emergency due to the potential for irreversible visual loss and stroke in the acute phase and aortic complications in the longer term. Prompt recognition of the condition and immediate initiation of glucocorticoids remain central to management and advances in therapy, particularly with tocilizumab in the first 12 months, have reduced glucocorticoid\u2010related morbidity. Upadacitinib has recently been shown in phase 3 trials to be effective, and its place in the Australasian therapeutic landscape will evolve in the coming years. Management also focusses on assessing for and reducing disease and treatment\u2010related complications, including relapse, aortic aneurysm, infection, diabetes and osteoporosis. The optimal treatment strategy beyond the initial 12 months of therapy remains undefined and is typically individualised and informed by comorbidities, patient preference, clinician familiarity, cost and regulatory access. This review outlines current best practice for the management of GCA in Australia with a focus on recent therapeutic advances and strategies for longer\u2010term patient care.<\/jats:p>","DOI":"10.1111\/imj.70315","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:04:02Z","timestamp":1769061842000},"page":"171-183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in management of giant cell arteritis"],"prefix":"10.1111","volume":"56","author":[{"given":"Ian","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Rheumatology Prince of Wales Hospital  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Caterson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Prince of Wales Hospital  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Sammel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Prince of Wales Hospital  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02450-w"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11472"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.142"},{"key":"e_1_2_13_5_1","first-page":"93","article-title":"The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis","volume":"22","author":"Gabriel SE","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449466"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1957.02970450023007"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1945-4"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003775"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2024.10.008"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401022"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413449"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez672"},{"key":"e_1_2_13_16_1","first-page":"104","article-title":"A probability score to aid the diagnosis of suspected giant cell arteritis","volume":"37","author":"Laskou F","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead698"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab102"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41774"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00152-1"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00265-5"},{"key":"e_1_2_13_22_1","unstructured":"Christ L..Treatment for Giant Cell Arteritis with Tocilizumab and 8 as Compared to 26\u2009Weeks of Prednisone (GISCO) (24 Feb 2025).Switzerland:National Library of Medicine;2025[cited 2025 Sep 27]. Available from URL:https:\/\/www.clinicaltrials.gov\/study\/NCT06833411?cond=Giant%20Cell%20Arteritis&viewType=Table&rank=13&sort=StudyFirstPostDate&limit=10&page=2."},{"key":"e_1_2_13_23_1","unstructured":"AbbVie.RINVOQ\u00ae (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA). [cited 2025 Sep 27]. Available from URL:https:\/\/news.abbvie.com\/2025-04-29-RINVOQ-R-upadacitinib-Receives-U-S-FDA-Approval-for-Giant-Cell-Arteritis-GCA."},{"key":"e_1_2_13_24_1","unstructured":"Roche.FDA approves Roche's Actemra\/RoActemra (tocilizumab) for giant cell arteritis 2017. [cited 2025 Sep 27]. Available from URL:https:\/\/www.roche.com\/media\/releases\/med-cor-2017-05-23."},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221113747"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2204"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab332"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42405"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1837-7"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/life11030258"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"e_1_2_13_32_1","unstructured":"Services Australia2025Giant cell arteritis \u2010 tocilizumab \u2010 initial authority application form (PB272) 2025[cited 2025 Sep 27]. Available from URL:https:\/\/www.servicesaustralia.gov.au\/pb272."},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10262"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-2-200101160-00010"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22754"},{"key":"e_1_2_13_37_1","article-title":"MEthotrexate versus TOcilizumab for treatment of Giant cell arteritis (METOGiA trial): a multicenter, randomized, controlled trial. (abstract)","author":"Samson M","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_13_38_1","unstructured":"MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter Randomized Controlled Trial: National Library of Medicine;2025[cited 2025 Nov 29]. Available from URL:https:\/\/clinicaltrials.gov\/study\/NCT03892785."},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1069013"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152166"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100072"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40044"},{"key":"e_1_2_13_43_1","unstructured":"Merkel P Langford C Krischer J.Abatacept for the Treatment of Giant Cell Arteritis: National Library of Medicine; [cited 2025 Sep 27]. Available from URL:https:\/\/www.clinicaltrials.gov\/study\/NCT04474847?cond=Giant%20Cell%20Arteritis&viewType=Table&rank=71&sort=StudyFirstPostDate&limit=10&page=8."},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221961"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa069"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.2.136"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221865"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03177-6"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203586"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00101-7"},{"key":"e_1_2_13_51_1","doi-asserted-by":"crossref","unstructured":"Novartis.Novartis provides update on Phase III GCAptAIN study of Cosentyx\u00ae in giant cell arteritis (GCA)2025[cited 2025 Sep 27]. Available from URL:https:\/\/www.novartis.com\/news\/media-releases\/novartis-provides-update-phase-iii-gcaptain-study-cosentyx-giant-cell-arteritis-gca.","DOI":"10.69645\/DQFX6833"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740500474537"},{"key":"e_1_2_13_53_1","unstructured":"Janssen.A Study to Evaluate Guselkumab for the Treatment of Participants With New\u2010onset or Relapsing Giant Cell Arteritis (THEIA): National Library of Medicine;2025[cited 2025 Sep 27]. Available from URL:https:\/\/www.clinicaltrials.gov\/study\/NCT04633447."},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24200"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03493-z"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05527-8"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102930"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.04.004"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00038-2"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2022-1214"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002923"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152508"},{"key":"e_1_2_13_63_1","first-page":"829","article-title":"Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real\u2010life study of 471 patients","volume":"41","author":"Calder\u00f3n\u2010Goercke M","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152174"},{"key":"e_1_2_13_65_1","unstructured":"Samson M.TocilizuMab discontinuAtion in GIant Cell Arteritis (MAGICA): National Library of Medicine;2025[cited 2025 Sep 27]. Available from URL:https:\/\/www.clinicaltrials.gov\/study\/NCT06037460?cond=Giant%20Cell%20Arteritis&viewType=Table&rank=6."},{"key":"e_1_2_13_66_1","first-page":"2025","article-title":"Efficacy and safety of upadacitinib in giant cell arteritis: 2\u2010year results from the re\u2010randomized, double\u2010blind SELECT\u2010GCA phase 3 trial (abstract)","volume":"77","author":"Schmidt W","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224543"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5535486"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-0679"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1384533"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70006"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11353"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab871"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202408"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key015"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103411"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2024.10.011"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001106"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2018.09.020"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.11.011"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52637"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev262"},{"key":"e_1_2_13_83_1","unstructured":"ATAGI.The Australian Immunisation Handbook: Department of Health and Aged Care Australian Government; [cited 2025 Sep 27]. Available from URL:https:\/\/immunisationhandbook.health.gov.au\/."},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1996-6"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152154"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335"},{"key":"e_1_2_13_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00560-2"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082115"},{"key":"e_1_2_13_89_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00004"},{"key":"e_1_2_13_90_1","first-page":"495","article-title":"A prospective, double\u2010blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera RF","year":"2001","journal-title":"Clin Exp Rheumatol"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.70315","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:21:59Z","timestamp":1770888119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/imj.70315"],"URL":"https:\/\/doi.org\/10.1111\/imj.70315","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}